Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

72.82
-1.3200-1.78%
Post-market: 72.820.00000.00%16:59 EDT
Volume:130.72K
Turnover:9.56M
Market Cap:1.64B
PE:21.91
High:74.65
Open:73.95
Low:72.60
Close:74.14
52wk High:99.50
52wk Low:56.71
Shares:22.47M
Float Shares:20.38M
Volume Ratio:0.47
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.32
EPS(LYR):3.32
ROE:16.16%
ROA:3.82%
PB:3.03
PE(LYR):21.93

Loading ...

ANI Pharmaceuticals Inc FY2026 Shr View $8.56, REV View $955.1 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Inc - 2025 Adj Non-Gaap Diluted EPS Expected $7.37 to $7.64

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Outlook FY Adjusted Ebitda USD 275-290 Million

THOMSON REUTERS
·
Jan 12

Corrected- ANI Pharmaceuticals Q4 Cortrophin Gel (Not Total Co) Revenue USD 111.4 Million (Removes Q4 Revenue Estimate)

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Inc - 2025 Net Revenues Expected Between $854 Mln and $873 Mln

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals (ANIP) Valuation Check After Robust 2025 Results And Raised Guidance

Simply Wall St.
·
Jan 10

ANI Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

ANI Pharmaceuticals SVP Chief HR Officer Krista Davis Reports Sale of Common Shares

Reuters
·
Dec 20, 2025

ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum

Simply Wall St.
·
Dec 20, 2025

Is ANI Pharmaceuticals Still Attractively Priced After Its Strong Multi Year Share Price Run?

Simply Wall St.
·
Dec 15, 2025

ANI Pharmaceuticals Sr. VP Meredith Cook Reports Sale of Common Shares

Reuters
·
Dec 13, 2025

Director Renee P. Tannenbaum Reports Sale of ANI Pharmaceuticals Inc. Common Shares

Reuters
·
Dec 10, 2025

ANI Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Dec 09, 2025

Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target

MT Newswires Live
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025

The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Governance Shake-Up And FutureVision Launch – Learn Why

Simply Wall St.
·
Dec 05, 2025

ANI Pharmaceuticals (ANIP): Valuation Check After Governance Shake-Up and New Rare Disease Strategy Moves

Simply Wall St.
·
Dec 03, 2025

BRIEF-ANI Pharmaceuticals Announces Board Transition

Reuters
·
Dec 01, 2025

ANI Pharmaceuticals' Chairman Patrick Walsh to Retire; Thomas Haughey Named Successor

MT Newswires Live
·
Dec 01, 2025